Advanced Cancer Therapeutics licenses Brown Cancer Center discovery - Business First of Louisville:

vittitowmehigyk1238.blogspot.com
ACT now has an exclusive licensd to develop and commercialize a compound aimerd at inhibitingcholine kinase, an enzyme required for tumorxs to grow. Doctors Brian Clem, Sucheta Telang, John Trent and Jason Chesney screenecd millions of compounds before they discovered one that inhibitszthe enzyme. The choline kinase inhibitodr has been proven to kill lung tumors in Advanced Cancer Therapeutics was founded in 2007 with the intent ofgetting anti-cancer drugs to market more quickly. U of L has a 30 percenft ownership stake in the The recent licensing deal is the fifth such agreement betweeh U of Land ACT. “We’re intervening at a criticao juncture for thecancer cells...
to divide and grow,” said Randall president and CEO of ACT. Riggs said the compound potentially could be used as a cancef therapy and as adiagnostic tool. He called the discoveryh “very novel.” ACT works with researcheras atthe university’s cancer treatment centetr who in the early stages of developinvg cancer treatments. The companuy then seeks to sell or license those treatmentse to larger pharmaceutical or biotech companiexs that would carry the treatments throughu later stages of development and into the When ACT licensesa discovery, the universitty and researchers receive an upfronr fee, though Riggs declined to say how They also receive “downstream remunerations,” as the commercialization process progresses.
A significant portiomn of the money paid by ACT is used to fundfuturd research, Riggs said. Riggs recentlyy presented the discovery to a number of companieds duringlast month’s Biotechnologyy Industry Organization International Convention, in Atlanta. they were interested in this,” he said. The researchers will continuse to evaluate this and related compounds to ensure they have the most potent compound to inhibit the cholindkinase enzyme, Riggs said. ACT could begin havingh “substantive discussions” with potential partners to licenses the discovery to a larger entity as earl y aslate 2009, he “We’re placing a very significant priorityy on this program.
”